| mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.31 |
3e-12 |
| mRNA |
IU1 |
CTRPv2 |
pan-cancer |
AAC |
0.25 |
3e-11 |
| mRNA |
tacrolimus |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
8e-08 |
| mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
4e-07 |
| mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
1e-06 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
2e-06 |
| mRNA |
Zebularine |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-06 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
6e-06 |
| mRNA |
etoposide |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
9e-06 |
| mRNA |
dabrafenib |
GDSC1000 |
pan-cancer |
AAC |
0.13 |
1e-05 |